Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Theodore A. Braich, Sydney E. Salmon, Aurelia Robertone, David S Alberts, Stephen E. Jones, Thomas P Miller, Harinder S. Garewal

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalInvestigational New Drugs
Volume4
Issue number3
DOIs
StatePublished - Sep 1986

Fingerprint

Colonic Neoplasms
Melanoma
Breast Neoplasms
Kidney
Lung
Agranulocytosis
esorubicin
Renal Cell Carcinoma
Lung Neoplasms
Neutrophils
Neoplasms

Keywords

  • esorubicin
  • phase II

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. / Braich, Theodore A.; Salmon, Sydney E.; Robertone, Aurelia; Alberts, David S; Jones, Stephen E.; Miller, Thomas P; Garewal, Harinder S.

In: Investigational New Drugs, Vol. 4, No. 3, 09.1986, p. 269-274.

Research output: Contribution to journalArticle

Braich, Theodore A. ; Salmon, Sydney E. ; Robertone, Aurelia ; Alberts, David S ; Jones, Stephen E. ; Miller, Thomas P ; Garewal, Harinder S. / Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. In: Investigational New Drugs. 1986 ; Vol. 4, No. 3. pp. 269-274.
@article{b759fb23517f4383b148dca9a370bee2,
title = "Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma",
abstract = "A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38{\%} of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.",
keywords = "esorubicin, phase II",
author = "Braich, {Theodore A.} and Salmon, {Sydney E.} and Aurelia Robertone and Alberts, {David S} and Jones, {Stephen E.} and Miller, {Thomas P} and Garewal, {Harinder S.}",
year = "1986",
month = "9",
doi = "10.1007/BF00179595",
language = "English (US)",
volume = "4",
pages = "269--274",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

AU - Braich, Theodore A.

AU - Salmon, Sydney E.

AU - Robertone, Aurelia

AU - Alberts, David S

AU - Jones, Stephen E.

AU - Miller, Thomas P

AU - Garewal, Harinder S.

PY - 1986/9

Y1 - 1986/9

N2 - A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

AB - A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

KW - esorubicin

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0023038013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023038013&partnerID=8YFLogxK

U2 - 10.1007/BF00179595

DO - 10.1007/BF00179595

M3 - Article

VL - 4

SP - 269

EP - 274

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -